0000950170-24-026868.txt : 20240306 0000950170-24-026868.hdr.sgml : 20240306 20240306071510 ACCESSION NUMBER: 0000950170-24-026868 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240306 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240306 DATE AS OF CHANGE: 20240306 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 24724361 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 tcrx-20240306.htm 8-K 8-K
false000178332800017833282024-03-062024-03-06

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

March 6, 2024

 

TSCAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-40603

82-5282075

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

830 Winter Street

 

Waltham, Massachusetts

 

02451

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code

857 399-9500

 

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Voting Common Stock, par value $0.0001 per share

 

TCRX

 

The Nasdaq Global Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

On March 6, 2023, TScan Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

Exhibit No.

Description

99.1

Press Release issued by TScan Therapeutics, Inc., dated March 6, 2024.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

TScan Therapeutics, Inc.

 

 

 

 

Date:

March 6, 2024

By:

/s/ Gavin MacBeath

 

 

 

Gavin MacBeath
Chief Executive Officer

 

 EX-99.1 2 tcrx-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

img207367504_0.jpg 

 

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

 

Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are relapse-free and show complete donor chimerism

 

Announced the clearance of two additional INDs for Solid Tumor Program: TSC-201-B0702 targeting MAGE-C2 on HLA-B*07:02 and TSC-204-A0101 targeting MAGE-A1 on HLA-A*01:01

 

Solid tumor clinical trial actively enrolling, with initial data for singleplex and multiplex cohorts anticipated in 2024

 

Expands leadership team with key appointments and promotions

 

Cash, cash equivalents, and marketable securities continues to fund operations into 2026

 

WALTHAM, Mass., Mar. 6, 2024 -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2023, and provided a business update.

 

“The advancements we made across our pipeline in 2023 have set the stage for a momentous year ahead as we continue to treat and follow patients in the heme malignancies study and commence patient dosing in the solid tumor program. We continue to make meaningful progress with our Phase 1 heme malignancies study, with updated data on eight treatment-arm patients and six control-arm patients presented at the Tandem Meetings of ASTCT and CIBMTR,” said Gavin MacBeath, Ph.D., Chief Executive Officer. “We are encouraged to see that none of the patients in the treatment arms has relapsed following treatment with TSC-100 or TSC-101, including one high-risk TP53-mutated MDS patient who has now reached one year of follow-up. The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life. We look forward to completing Phase 1 enrollment and reporting clinical and translational data in 2024 with two-year relapse-free survival data in 2025.”

 

“We are on-track to treat the first patient in our Phase 1 solid tumor program this month, which will bring us one step closer to delivering customized, enhanced, multiplexed TCR-T therapies to patients with a variety of solid tumors,” said Debora Barton, M.D., Chief Medical Officer. “Solid tumors are notoriously heterogenous, with tumors frequently expressing more than one target antigen. We believe the only way to eradicate solid tumors is through a multi-targeted approach. To make this a reality, we continue to prioritize expanding the ImmunoBank with additional TCRs to increase patient eligibility for multiplexed therapy. With recent FDA clearance of our INDs for TSC-201-B0702 and TSC-204-A0101, we now have six TCR-Ts cleared for clinical development. We look forward to continuing to advance the solid tumor program and sharing data on patients from singleplex and multiplex cohorts in 2024.”

 

Recent Corporate Highlights

 

•
In February 2024, the Company presented updated Phase 1 clinical results on lead TCR-T candidates TSC-100 and TSC-101 at the Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®).

 

 

o
Data showed that all eight (100%) treatment-arm patients were free from relapse, including four patients with follow-up beyond ten months. Notably, one high-risk TP53-mutated MDS patient has now reached the one-year mark following treatment with TSC-101. Additionally, no patient-derived hematopoietic cells were detected in any of the eight treatment-arm patients, indicating complete elimination of target cells. One AML patient with detectable disease post-transplant converted to, and continues to show, no detectable disease following treatment with TSC-101, with the most recent measurement at day 180. Patients have now been enrolled up to the third and final dose level in both treatment arms with no dose limiting toxicities thus far, suggesting that the third dose level will likely become the recommended Phase 2 dose.
o
Of the six patients enrolled in the control arm (transplant alone), two control-arm patients relapsed at day 161 and day 180, and one of them succumbed to the relapse on day 265 post-transplant. A third control-arm patient required clinical intervention on day 133 because of concerns of impending relapse, and only two of the control-arm patients achieved and maintained complete donor chimerism following transplantation.
o
The Company hosted a virtual KOL event following the Tandem Meetings to discuss these data. A replay of the event can be found here.

 

•
The Company recently received U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) applications for two additional TCR-Ts in their Solid Tumor Program:

 

o
TSC-201-B0702, a TCR-T targeting melanoma-associated antigen C2 (MAGE-C2) on HLA -B*07:02
o
TSC-204-A0101, a TCR-T targeting melanoma-associated antigen 1 (MAGE-A1) on HLA-A*01:01

 

With the clearance of these IND applications, TScan now has six enhanced TCR-Ts cleared for clinical development. The Company remains on-track to dose the first patient in its Phase 1 solid tumor program in the first quarter of 2024 and anticipates sharing initial data on patients from both the singleplex and multiplex cohorts in 2024.

 

•
The Company will present two “Trials in Progress” poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024. Details for the posters include:

 

Title: Trial in progress: A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation

Session Title: Phase I Clinical Trials in Progress 2

Session Date and Time: Monday April 8, 2024; 1:30 - 5:00 PM PDT

Location: Poster Section 50

Poster Board Number: 2

Abstract Presentation Number: CT151

 

Title: Trial in progress: A phase 1, first in human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors

Session Title: Phase I Clinical Trials in Progress 2
Session Date and Time: Monday April 8, 2024; 1:30 - 5:00 PM PDT

Location: Poster Section 50

Poster Board Number: 21

Abstract Presentation Number: CT170

 

•
The Company continues to expand its leadership team with key appointments and promotions:

 

o
Appointed Jason A. Amello as Chief Financial Officer
o
Appointed Justin McCue, Ph.D., as Chief Technology Officer
o
Promoted Zoran Zdraveski, J.D., Ph.D., to Chief Legal and Strategy Officer
o
Appointed R. Keith Woods to its Board of Directors

 

o
Promoted Cagan Gurer, Ph.D., to Senior Vice President, Discovery
o
Promoted Jim Murray to Senior Vice President, Head of Development Operations
o
Appointed Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

 

•
In November 2023, the Company was named a Top Place to Work by The Boston Globe for the second consecutive year.

 

Upcoming Anticipated Milestones

 

Heme Malignancies Program: TScan’s two lead TCR-T cell therapy candidates, TSC-100 and TSC-101, are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic syndromes (MDS) undergoing hematopoietic cell transplantation (HCT) (NCT05473910).

 

•
Plans to open expansion cohorts at the recommended Phase 2 dose level to further characterize safety and evaluate translational and efficacy endpoints in the third quarter of 2024.
•
Plans to complete Phase 1 enrollment and report one-year clinical and translational data on initial patients in 2024.
•
Expects to initiate registration trial and report two-year relapse data in 2025.

 

Solid Tumor Program: TScan continues to expand the ImmunoBank, a collection of therapeutic TCRs that target different cancer-associated antigens presented on diverse HLA types. TScan’s strategy is to treat patients with multiple TCR-Ts to overcome tumor heterogeneity and prevent resistance that may arise from either target or HLA loss (screening protocol: NCT05812027) (treatment protocol: NCT05973487).

 

•
Initiated Phase 1 solid tumor clinical study and expects to dose the first patient in the first quarter of 2024.
•
Expects to share initial data on patients from both singleplex and multiplex cohorts in 2024.
•
Plans to continue to expand the ImmunoBank with additional IND filings throughout 2024.
•
Long-term duration of response data for multiplexed therapy anticipated in 2025.

 

Financial Results

 

Revenue: Revenue for the fourth quarter of 2023, was $7.2 million, compared to $3.1 million for the fourth quarter of 2022, and $21.0 million for the full-year 2023, compared to $13.5 million for the full-year 2022. The increase in both periods is primarily due to timing of research activities related to the collaboration agreement with Amgen which commenced in May 2023 compared to the collaboration and license agreement with Novartis which ended in March 2023.

 

R&D Expenses: Research and development expenses for the fourth quarter of 2023 were $22.4 million, compared to $15.6 million for the fourth quarter of 2022, and $88.2 million for the full-year 2023, compared to $59.8 million for the full-year 2022. The period over period increases were primarily driven by increased costs associated with clinical trial start-up fees and patient enrollment, increased personnel costs, and expansion of facilities.

 

G&A Expenses: General and administrative expenses for the fourth quarter of 2023, were $6.2 million, compared to $6.1 million for the fourth quarter of 2022, and $26.4 million for the full-year 2023, compared to $20.4 million for the full-year 2022. The full-year increase of $6.0 million was primarily driven by increased legal and professional fees and expansion of facilities.

 

Net Loss: Net loss was $19.6 million for the fourth quarter of 2023, compared to $18.7 million for the fourth quarter of 2022, and included net interest income of $1.7 million and $0, respectively. Net loss for the full-year 2023 was $89.2 million, compared to $66.2 million for the full-year 2022, and included net interest income of $4.2 million and $0.4 million, respectively.

 

 

Cash Position: Cash, cash equivalents, and marketable securities as of December 31, 2023 were $192.0 million, excluding $5.0 million of restricted cash. The Company believes that its existing cash resources will be sufficient to fund its current operating plan into 2026.

 

Share Count: As of December 31, 2023, the Company had issued and outstanding shares of 47,829,529, which consists of 43,552,941 shares of voting common stock and 4,276,588 shares of non-voting common stock, and outstanding pre-funded warrants to purchase 47,010,526 shares of voting common stock at an exercise price of $0.0001 per share.

 

About TScan Therapeutics, Inc.

 

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of cancers.

 

Forward-Looking Statements

 

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company’s plans, progress, and timing relating to the Company’s hematologic malignancies program, including potential indicators of treatment success, completion of enrollment and opening of expansion cohorts, and the presentation of data; the Company’s plans, progress, and timing relating to the Company’s solid tumor programs, including treatment of patients and the presentation of data; the Company’s current and future research and development plans or expectations; the structure, timing and success of the Company’s planned preclinical development, submission of INDs, and clinical trials; the potential benefits of any of the Company’s proprietary platforms, multiplexing, or current or future product candidates in treating patients; the Company’s ability to fund its operating expenses and capital expenditure requirements with its existing cash and cash equivalents; and the Company’s goals and strategy, focus, and anticipated financial performance. TScan intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan,” “on track,” or similar expressions or the negative of those terms. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. The express or implied forward-looking statements included in this release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of TScan’s TCR-T therapy candidates; TScan’s expectations regarding its preclinical studies being predictive of clinical trial results; TScan’s recently approved INDs being indicative or predictive of bringing TScan closer to its goal of providing customized TCR-T therapies to treat patients with cancer; the timing of the launch, initiation, progress, expected results and announcements of TScan’s preclinical studies, clinical trials and its research and development programs; TScan’s timeline regarding its filing of INDs for its TCRs throughout the year; TScan’s ability to enroll patients for its clinical trials within its expected timeline; TScan’s plans relating to developing and commercializing its TCR-T therapy candidates, if approved, including sales strategy; estimates of the size of the addressable market for TScan’s TCR-T therapy candidates; TScan’s manufacturing capabilities and the scalable nature of its manufacturing process; TScan’s estimates regarding expenses, future milestone payments and revenue, capital requirements and needs for additional financing; TScan’s expectations regarding competition; TScan’s anticipated growth strategies; TScan’s ability to attract or retain key personnel; TScan’s ability to establish and maintain development partnerships and collaborations; TScan’s expectations regarding federal, state and foreign regulatory requirements; TScan’s ability to obtain and maintain intellectual property protection for its proprietary platform technology and our product candidates; the sufficiency of TScan’s existing capital resources

 

to fund its future operating expenses and capital expenditure requirements; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of TScan’s most recent Annual Report on Form 10-K and any other filings that TScan has made or may make with the SEC in the future. Any forward-looking statements contained in this release represent TScan’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements.

 

Contacts

 

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com 

 

Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com 

 

TScan Therapeutics, Inc.

 

Condensed Consolidated Balance Sheet Data

 

(in thousands)

 

 

 

 

 

 

 

 

 

 

December 31, 2023

 

 

December 31, 2022

 

Assets

 

 

 

 

 

 

Cash, cash equivalents, and marketable securities

 

$

192,044

 

 

$

120,027

 

Other assets

 

 

80,105

 

 

 

79,064

 

Total assets

 

 

272,149

 

 

 

199,091

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

Total liabilities

 

 

121,282

 

 

 

99,657

 

Total stockholders' equity

 

 

150,867

 

 

 

99,434

 

Total liabilities and stockholders' deficit

 

$

272,149

 

 

$

199,091

 

 

 

TScan Therapeutics, Inc.

 

Condensed Consolidated Statements of Operations

 

(in thousands, except share and per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended December 31,

 

 

Twelve Months Ended December 31,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Collaboration and license revenue

 

$

7,211

 

 

$

3,096

 

 

$

21,049

 

 

$

13,535

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

22,407

 

 

 

15,604

 

 

 

88,153

 

 

 

59,819

 

General and administrative

 

 

6,161

 

 

 

6,140

 

 

 

26,354

 

 

 

20,352

 

Total operating expenses

 

 

28,568

 

 

 

21,744

 

 

 

114,507

 

 

 

80,171

 

Loss from operations

 

 

(21,357

)

 

 

(18,648

)

 

 

(93,458

)

 

 

(66,636

)

Interest and other income, net

 

 

2,596

 

 

 

900

 

 

 

7,999

 

 

 

1,591

 

Interest expense

 

 

(852

)

 

 

(975

)

 

 

(3,759

)

 

 

(1,176

)

Net loss

 

$

(19,613

)

 

$

(18,723

)

 

$

(89,218

)

 

$

(66,221

)

Net loss per share, basic and diluted

 

$

(0.21

)

 

$

(0.78

)

 

$

(1.36

)

 

$

(2.75

)

Weighted average common shares outstanding—basic and diluted

 

 

94,835,735

 

 

 

24,077,857

 

 

 

65,599,858

 

 

 

24,048,267

 

 

 

 

 

 

 GRAPHIC 3 img207367504_0.jpg GRAPHIC begin 644 img207367504_0.jpg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end EX-101.SCH 4 tcrx-20240306.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Address, State or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Entity Ex Transition Period Entity Ex Transition Period Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation State Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre-commencement Tender Offer Pre Commencement Tender Offer Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Securities Act File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Security 12b Title Document Type Document Type XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Mar. 06, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001783328
Document Type 8-K
Document Period End Date Mar. 06, 2024
Entity Registrant Name TSCAN THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-40603
Entity Tax Identification Number 82-5282075
Entity Address, Address Line One 830 Winter Street
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code 857
Local Phone Number 399-9500
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Voting Common Stock, par value $0.0001 per share
Trading Symbol TCRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports tcrx-20240306.htm tcrx-20240306.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tcrx-20240306.htm": { "nsprefix": "tcrx", "nsuri": "http://www.tscan.com/20240306", "dts": { "inline": { "local": [ "tcrx-20240306.htm" ] }, "schema": { "local": [ "tcrx-20240306.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_a558e856-2071-4abb-b2ae-536fbc0c2786", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tcrx-20240306.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a558e856-2071-4abb-b2ae-536fbc0c2786", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tcrx-20240306.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.tscan.com/20240306/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0000950170-24-026868-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-026868-xbrl.zip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end XML 15 tcrx-20240306_htm.xml IDEA: XBRL DOCUMENT 0001783328 2024-03-06 2024-03-06 false 0001783328 8-K 2024-03-06 TSCAN THERAPEUTICS, INC. DE 001-40603 82-5282075 830 Winter Street Waltham MA 02451 857 399-9500 false false false false Voting Common Stock, par value $0.0001 per share TCRX NASDAQ true false